SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-120332"
 

Search: onr:"swepub:oai:DiVA.org:liu-120332" > Final 10-year resul...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Sonnenblick, AmirUniversity of Libre Bruxelles, Belgium (author)

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer

  • Article/chapterEnglish2015

Publisher, publication year, extent ...

  • Elsevier,2015
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-120332
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-120332URI
  • https://doi.org/10.1016/j.ejca.2015.03.018DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|Sanofi Aventis; Associazione Italiana Ricerca Cancro (AIRC), Milan, Italy
  • Aim: Breast International Group (BIG) 2-98 is a randomised phase III trial that tested the effect of adding docetaxel, either in sequence to or in combination with anthracycline-based adjuvant chemotherapy, in women with node-positive breast cancer (BC). Here, we present the 10-year final trial safety and efficacy analyses. We also report an exploratory analysis on the predictive value of Ki67 for docetaxel efficacy, in the BIG 2-98 and using a pooled analysis of three other randomised trials. Patients and methods: 2887 patients were randomly assigned in a 2 x 2 trial design to one of four treatments. The primary objective was to evaluate the overall efficacy of docetaxel on disease free survival (DFS). Secondary objectives included comparisons of sequential docetaxel versus sequential control arm, safety and overall survival (OS). Ki67 expression was centrally evaluated by immunohistochemistry. Results: After a median follow-up of 10.1 years, the addition of docetaxel did not significantly improve DFS or OS (hazard ratio (HR) = 0.91, 95% confidence interval (CI) = 0.81-1.04; P = 0.16 and HR = 0.88, 95% CI = 0.76-1.03; P = 0.11, respectively). Sequential docetaxel did not improve DFS compared to the sequential control arm (HR = 0.86, 95% CI = 0.721.03; P = 0.10). In oestrogen receptor (ER)-positive tumours with Ki67 greater than= 14%, the addition of docetaxel resulted in 5.4% improvement in 10-year OS (P = 0.03, test for interaction = 0.1). In a multivariate model, there was a trend for improved DFS and OS in ER-positive patients with high Ki67 and treated with docetaxel (HR = 0.79, 95% CI = 0.63-1.01; P = 0.05 and HR = 0.76, 95% CI = 0.57-1.01; P = 0.06, respectively). A pooled analysis of four randomised trials showed a benefit of taxanes in highly proliferative ER-positive disease but not in low proliferating tumours (interaction test P = 0.01). Conclusion: The DFS benefit previously demonstrated with sequential docetaxel is no longer observed at 10 years. However, an exploratory analysis suggested a benefit of docetaxel in patients with highly proliferative ER-positive BC.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Francis, Prudence A.Peter MacCallum Cancer Centre, Australia; Australia and New Zealand Breast Cancer Trials Grp, Australia; Int Breast Cancer Study Grp, Switzerland (author)
  • Azim, Hatem A. Jr.University of Libre Bruxelles, Belgium (author)
  • de Azambuja, EvandroUniversity of Libre Bruxelles, Belgium (author)
  • Nordenskjöld, BoLinköpings universitet,Avdelningen för kliniska vetenskaper,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US(Swepub:liu)bono64 (author)
  • Gutierez, JorgeClin Las Condes, Chile (author)
  • Quinaux, EmmanuelInt Institute Drug Dev, Belgium (author)
  • Mastropasqua, Mauro G.University of Milan, Italy; University of Milan, Italy (author)
  • Ameye, LievekeUniversity of Libre Bruxelles, Belgium (author)
  • Anderson, MichaelCopenhagen University Hospital, Denmark; Danish Breast Cancer Cooperat Grp, Denmark (author)
  • Lluch, AnaUniversity of Valencia, Spain (author)
  • Gnant, MichaelMedical University of Vienna, Austria; Medical University of Vienna, Austria (author)
  • Goldhirsch, AronEuropean Institute Oncol, Italy; Int Breast Cancer Study Grp, Switzerland (author)
  • Di Leo, AngeloHospital Prato, Italy (author)
  • Barnadas, AgustiUniversity of Autonoma Barcelona, Spain (author)
  • Cortes-Funes, HernanUniversity Hospital 12 Octubre, Spain (author)
  • Piccart, MartineUniversity of Libre Bruxelles, Belgium (author)
  • Crown, JohnSt Vincets University Hospital, Ireland (author)
  • University of Libre Bruxelles, BelgiumPeter MacCallum Cancer Centre, Australia; Australia and New Zealand Breast Cancer Trials Grp, Australia; Int Breast Cancer Study Grp, Switzerland (creator_code:org_t)

Related titles

  • In:European Journal of Cancer: Elsevier51:12, s. 1481-14890959-80491879-0852

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view